Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 8, 2009, Pages 902-907

  Murthy, Gowdara Divakara ^a,d   Vu, Khoa ^b   Venugopal, Sushma ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Hospitalist   (United States)

^c State University of New York Health Science Center   (United States)

^d STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Hyperlipidemia; Prevalence and treatment

Indexed keywords

ANTILIPEMIC AGENT; VIRUS ANTIBODY; VIRUS RNA; ANTIVIRUS AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; HEPATITIS C, CHRONIC; HYPERLIPIDEMIAS; LIVER FUNCTION TEST; MIDDLE AGED; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERLIPIDEMIAS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 67651008706     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32831b4698     Document Type: Article

References (26)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23:437.
2. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005; 28:2548-2550. (Pubitemid 41384312)
3. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21:1135.
4. Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996; 32:526. (Pubitemid 26280438)
5. Grimbert S, Valensi P, Levy-Marchal C. High prevalence of diabetes in patients with chronic hepatitis C. A case control study. Gastroenterol Clin Biol 1996; 20:544.
6. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis virus C infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840. (Pubitemid 38298332)
7. Chalasani N, Aljadhey H, Kesterson J. Patients with elevated liver enzymes are not at high risk for statin hepatotoxicity. Gastroenterology 2004; 126:1287-1292. (Pubitemid 38552793)
8. Khorashadi S, Hasson NK, Cheung RC. What is the risk of developing hepatotoxicity from statin therapy in hyperlipidemic patients with hepatitis C? Clin Gastroenterol Hepatol 2006; 4:902-907.
9. Russo M, Jacobson IM. How to use statins in patients with chronic liver disease. Cleveland Clin J Med 2002; 71:58-62.
10. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97:77C-81C.
11. Litvin CB. In the dark - the case for electronic health records. N Engl J Med 2007; 356:2454-2455.
12. Grundy SM, Cleeman JI, Merz NB, Brewer H Jr, Clark L, Hunninghake R, et al. Implications of Recent Clinical Trials for The National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-732.
13. Glantz SA. Primer of Biostatistics. 5th ed. Columbus, Ohio, USA: McGraw Hill; 2002.
14. Tanner M, Link N. Hyperlipidemia: evaluation and dietary management. West J Med 2001; 175:246-250.
15. Carrol M, Lacher D, Sorlie P, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294:1773-1781.
16. Kowdley K. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin Liver Dis 1998; 2:3-5.
17. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103-1109.
18. Fiore G, Fera G, Napoli N, et al. Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996; 8:125-129.
19. Cheung R. Epidemiology of hepatitis C infection in American Veterans. Am J Gastroenterol 2000; 95:740. (Pubitemid 30123913)
20. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of viral hepatitis C infection in the United States. NEJM 1999; 341:556-562.
21. Fedder DO, Koro CE, Italien GJ. New National Cholesterol Education III Guidelines for Primary Prevention. Lipid-lowering drug therapy. Circulation 2002; 105:152-156.
22. Bader T, Madhoun M, Rizvi S. Retrospective Analysis of the effect of taking a statin along with peginterferon and ribavirin (PI + R) On SVR. Digestive Diseases Week 2007 (DDW 2007), Washington DC. 19-24 May. Abstract M1845.
23. Apostolos H, Christos S, Georgia L. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23:131-134.
24. Muntner P, Desalvo KB, Wildman RP, Raggi P, He J, Whelton PK. Trends in the prevalence, awareness, treatment and control of cardiovascular disease risk factors among non-institutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol 2006; 163:913-920. (Pubitemid 43752357)
25. Ford ES, Mokdad AH, Giles WH, Mensah G. Serum total cholesterol concentrations and awareness, treatment and control of hypercholesterolemia among US adults. Circulation 2003; 107:2185.
26. Mehler PS, Esler A, Estacio RO, Mackenzie TD, Hiatt WR, Schrier RW. Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes mellitus. Am J Med 2003; 114:377-382. (Pubitemid 36513686)